Shaji Kumar, MD

Articles

Clinical Pearls and Future Directions in AL Amyloidosis

January 22nd 2024

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

January 22nd 2024

Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.

Adverse Event Management in AL Amyloidosis

January 15th 2024

Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

January 15th 2024

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Birtamimab Safety Profile in the VITAL Study

January 8th 2024

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

January 8th 2024

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

Limitations of Available Treatment Options for Patients with Cardiac Involvement

January 8th 2024

Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.

Treatment Approaches in AL Amyloidosis

January 8th 2024

Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.

Navigating the Differential Diagnosis of AL Amyloidosis

December 20th 2023

Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.

AL Amyloidosis: Background, Patient Profile, and Staging

December 20th 2023

Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.

Unmet Needs in the Treatment of NDMM and R/R MM and Clinical Pearls for Community Oncologists

January 17th 2023

The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.

Treatment Options for MM at Early Relapse

January 17th 2023

Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.

Key Considerations for Patients with Multiple Myeloma During the Treatment Journey

January 10th 2023

Jenny Ahlstrom, a patient with multiple myeloma, shares considerations for patients going through treatment, including toxicities, follow-up, and travel planning.

Available Induction Treatment Regimens for Patients with Transplant-Ineligible MM

January 10th 2023

Shaji Kumar, MD, and Krina Patel, MD, discuss the treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for stem cell transplant.

Optimal Treatment Selection for Patients with NDMM: Updates from IMS 2022

January 3rd 2023

Dr Krina Patel discusses updates in the treatment of newly-diagnosed from recent meetings how the appropriate treatments are selected in patients with newly-diagnosed multiple myeloma.

The Role of Stem Cell Transplant in the NDMM Treatment Landscape

January 3rd 2023

Dr Shaji Kumar reviews clinical trial data on the role of stem cell transplant as a treatment for newly-diagnosed multiple myeloma in tandem with a multi-agent combination therapy.

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

December 22nd 2022

Shaji Kumar, MD, reviews the results of the phase 3 study evaluating the use of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

December 19th 2022

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Introduction to Multiple Myeloma and Resources for Patient Education after Diagnosis

December 19th 2022

Shaji Kumar, MD, provides an overview of multiple myeloma, and Jenny Ahlstrom, a patient with multiple myeloma, shares the story of her diagnosis and the resources she used to educate herself.

Future Perspectives in Biomarker Identification and Testing in MM

August 24th 2022

Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.